Solid Biosciences LLC

Yahoo Finance • 2 days ago

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

- Non-exclusive license for Solid’s proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio’s gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an upfront payment and is... Full story

Yahoo Finance • 28 days ago

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announce... Full story

Yahoo Finance • last month

Solid Biosciences’ SWOT analysis: promising DMD gene therapy stock faces pivotal year

Solid Biosciences Inc. (NASDAQ:SLDB) is entering a critical phase in its development of gene therapies for rare neuromuscular and cardiac diseases. The biotechnology company’s lead candidate, SGT-003 for Duchenne muscular dystrophy (DMD),... Full story

Yahoo Finance • last month

Sarepta Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of approximately $2 billion and... Full story

Yahoo Finance • last month

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 - - FA (SGT-212): Phase 1b trial initiation expected in Q4 20... Full story

Yahoo Finance • 2 months ago

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive day on Monday, jumping 10 percent to... Full story

Yahoo Finance • 2 months ago

Solid Biosciences' SWOT analysis: gene therapy stock poised for growth amid challenges

Solid Biosciences Inc. (NASDAQ:SLDB), with a market capitalization of $544 million, is a genetic medicine company at the forefront of developing innovative gene therapies for rare neuromuscular and cardiac diseases. With a primary focus o... Full story

Yahoo Finance • 2 months ago

Sarepta Therapeutics' SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of $1.36 billion and a stock th... Full story

Yahoo Finance • 2 months ago

Solid Biosciences gets FDA fast track status for heart disease therapy

[Glass bottles in production in the tray of an automatic liquid dispenser, a line for filling medicines against bacteria and viruses, antibiotics and vaccines] aleksejplatonov/iStock via Getty Images * Solid Biosciences (NASDAQ:SLDB [ht... Full story

Yahoo Finance • 2 months ago

Solid Biosciences stock rating reiterated at Market Outperform by JMP

Investing.com - JMP Securities has reiterated its Market Outperform rating on Solid Biosciences (NASDAQ:SLDB) with a price target of $15.00. The stock has shown remarkable momentum, gaining nearly 97% over the past six months and about 1... Full story

Yahoo Finance • 2 months ago

Solid Biosciences' SWOT analysis: gene therapy stock shows promise amid challenges

Solid Biosciences Inc. (NASDAQ:SLDB), a genetic medicine company focused on developing gene therapies for neuromuscular and cardiac diseases, has been attracting significant attention from investors and analysts alike. According to Invest... Full story

Yahoo Finance • 2 months ago

Citi maintains Buy rating on Solid Biosciences stock amid Elevidys safety concerns

Investing.com - Citi has reiterated a Buy rating and $14.00 price target on Solid Biosciences (NASDAQ:SLDB) stock, which has surged over 70% in the past six months and currently trades at $5.58. The renewed rating comes following safety... Full story

Yahoo Finance • 3 months ago

Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT

Solid Biosciences Inc. (NASDAQ:SLDB) is one of the best stocks to invest in for a quick return.Solid Biosciences Inc. (NASDAQ:SLDB) Robotic arms performing diagnostic tests in a healthcare technology lab. Citi initiated coverage on Solid... Full story

Yahoo Finance • 3 months ago

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA - - Solid expect... Full story

Yahoo Finance • 3 months ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of... Full story

Yahoo Finance • 3 months ago

Solid Biosciences' SWOT analysis: gene therapy stock shows promise amid DMD competition

Solid Biosciences Inc. (NASDAQ:SLDB), a biotechnology company with a market capitalization of $350 million focused on developing gene therapies for rare diseases, has been making significant strides in its pursuit of treatments for Duchen... Full story

Yahoo Finance • 4 months ago

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

- Duchenne (SGT-003): Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second h... Full story

Yahoo Finance • 7 months ago

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

- Duchenne: Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potentia... Full story

Yahoo Finance • 7 months ago

Solid Biosciences Announces Pricing of Underwritten Offering

CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announce... Full story

Yahoo Finance • 7 months ago

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

— Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial — — Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed s... Full story